FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
32.72 USD
0 (0%)
2024 Q4
2024 Q3
2024 Q2
2024 Q1
201.27M
186.04M
172.81M
154.62M
54.41M
42.78M
38.1M
33.45M
146.86M
143.26M
134.71M
121.17M
91.13M
81.55M
113.35M
69.14M
34.67M
25.39M
63.58M
22.19M
56.47M
56.16M
49.77M
46.95M
27.6M
27.58M
28.51M
27.23M
28.86M
28.59M
27.22M
25.68M
0
0
37k
-141k
55.73M
61.71M
21.36M
52.03M
428k
460k
338k
-248k
56.16M
62.17M
21.69M
51.78M
6.68M
16.08M
10.1M
13.45M
49.48M
46.09M
11.59M
38.33M
0.87
0.81
0.2
0.68
0.85
0.79
0.2
0.67
57.1M
56.87M
56.8M
56.77M
58.22M
58.1M
57.54M
57.6M
66.33M
72.49M
27.41M
58.16M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
-47.26M
-93.35M
-104.94M
-143.28M
49.48M
46.09M
11.59M
38.33M
0
269k
-269k
0
0
0
0
0
2.22M
-47.26M
-93.35M
-104.94M
49.48M
46.36M
11.32M
38.33M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
1.26M
750k
3.26M
3.26M
5.97M
5.97M
6.05M
6.12M
-513k
-3k
-632k
-5k
-4.2M
-5.21M
-2.16M
-2.86M
2024 Q4
2024 Q3
2024 Q2
2024 Q1
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.